Moderna Inc. announced on Wednesday that clinical data on its Omicron-containing bivalent COVID booster candidate had shown a better and higher neutralizing response against that variant, even one month after administration, compared to the original mRNA-1273 vaccine.
"We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer," said Stéphane Bancel, Chief Executive Officer of Moderna. "Taken together, our bivalent booster candidates demonstrate the power of Moderna's mRNA platform to develop vaccines that meet immediate, global public health threats."
Moderna's shares were up 1.06% after the announcement, at 7:26 am ET, to sell for $146.88.
